Verdict: FILTER | Memo LR: 0.7 | Weight: 0.40%

Edge type: Structural (index construction arbitrage) + temporal (15-week window aligns with Q1 trough). No informational edge.

Factor type: EXECUTION (60-120d half-life). Q1 earnings landmine + cocoa hedge disadvantage + NA volume weakness.

Key catalyst: Apr 28 Q1 earnings — ≈$1B EBIT inventory adjustment.

Factor Decomposition (iev regress MDLZ, 250d)

SPY    beta = +0.56     5.5% of variance
MTUM   beta = -0.38    anti-momentum
Idio              96.2% of variance

alpha = -11.1% annualized
sigma_idio = 22.1%
R-squared = 3.8%
QQQ beta ~ 0.04

96% idiosyncratic. The -11.1% trailing alpha is MDLZ losing on its own fundamentals, not factor drag. Anti-momentum loading (-0.38) confirms persistent underperformance trend.

QQQ beta ~ 0.04 is the structural case. MDLZ contributes 0.016% of QQQ's beta exposure while consuming 0.40% of weight. It is 27x less capital-efficient at delivering QQQ-like returns than the average constituent.

Verified Financials (8-K 2026-02-03, 10-K 2026-02-04)

FY2025

Q4 2025

Revenue $10,496M (+9.3%), organic +5.1%. Gross margin 28.2% reported (-1,040 bps), 30.5% adjusted (-100 bps). Diluted EPS $0.51 reported (-60.8%), $0.72 adjusted (+4.6% CC).

North America FY2025 (Weakest Segment)

Revenue $10,679M (-2.1%), organic -1.9% (Vol/Mix -2.7pp, Pricing +0.8pp). Operating Income $1,904M (-23.6%, down $588M). Worst regional performer.

Income Bridge

Input costs $3,621M exceeded pricing gains $2,892M by $729M. Volume/mix drag $890M additional. M2M derivatives $1,884M unfavorable swing ($1,341M loss in 2025 vs $543M gain in 2024). Derivative book now ≈$502M net liability (was $683M net asset in 2024).

2026 Guidance

• Organic net revenue: flat to +2%
• Adjusted EPS: flat to +5% on CC basis (implies $2.92-$3.07 adj, +$0.06 FX, range $2.98-$3.13)
• Free cash flow: ≈$3B
• "Does not reflect any potential tariff changes to USMCA compliant trade."

Q1 2026 Setup

Consensus adj EPS $0.61. CFO Zaramella: "a one-time adjustment that takes place on the inventory, and that is causing in the first February, but predominantly in Q1, an impact that is at a billion dollars." Resets inventory from 2025 exit costs to 2026 pipeline costs. Europe customer disruption in H1 from annual negotiations.

Buyback

Q4 2025: 9,021,154 shares at avg $54.71. $9B program through Dec 2027. $6.7B remaining. ≈$575M/quarter pace.

The Bear Case (15-week window: Mar 27 -- Jul 10, 2026)

1. Q1 Earnings Landmine (Apr 28) | LR 0.7

≈$1B EBIT hit resets inventory to 2026 pipeline costs. Consensus adj EPS $0.61. Reported EPS will be far worse -- FY25 showed 35% gap between reported ($1.89) and adjusted ($2.92). Q1 reported could be near-zero or negative.

Known hit, partially priced. But magnitude still shocks holders who parse headlines not footnotes. Bloomberg terminals flash reported first.

2. Cocoa Hedge Trap | LR 0.8

CEO: "we're already covered for 2026. There's not a lot we can do anymore." CFO: "Our pipeline cost for 2026 is determined at this point in time. And it is clearly at a higher than the current cocoa spot."

Cocoa spot ≈$3,000/ton. MDLZ hedged well above. CAGNY (Feb 17): CEO cited "pricing mismatch" -- competitors and customers will pressure pricing. Ghana/Ivory Coast producer prices being cut. No margin benefit from declining cocoa until 2027. Competitive risk from unhedged players who can now price below MDLZ.

This is the closest thing to a non-consensus signal. Analysts covering MDLZ in isolation focus on MDLZ's cost structure. The competitive dynamic -- unhedged peers undercutting on price while MDLZ is locked in -- requires cross-referencing with HSY, NSRGY, Lindt. Second-order, not widely modeled.

3. NA Biscuit Volume Collapse | LR 0.8

CEO: "biscuit category is showing a soft volume. It was the last three months, it's down 4% in volume." Consumer confidence "near historic low" -- prioritizing basics over snacking.

Management expects no volume growth in NA biscuits for H1 2026, "moderation of decline in H2." Shifted strategy away from promotions in 2025 (better margins, lost share). 2026 plan: more brand investment, innovation (Biscoff), channel expansion -- gradual, not immediate.

4. Factor Misfit / Index Construction Arbitrage | LR 0.7

QQQ beta ~ 0.04. SPY beta = 0.56. MTUM beta = -0.38 (anti-momentum). Consumer staple paying 3.47% dividend in a growth/tech index.

In QQQ rally: dead weight. In QQQ selloff: "holds up" but QQQ benchmark drops too -- no filtration alpha. Only scenario where keeping MDLZ helps: QQQ crashes AND MDLZ outperforms. At 0.40% weight: max benefit ≈2 bps.

The counterparty is the index methodology, not an informed investor.

5. Trailing Alpha -11.1% Annualized | LR 0.7

Persistent negative alpha over 250 days. 96% idiosyncratic -- MDLZ-specific, not factor rotation. RSI 50.4 (neutral) -- no oversold mean-reversion signal to fight the trend.

6. USMCA Tariff Tail Risk | LR 0.8

2026 outlook explicitly "does not reflect any potential tariff changes to USMCA compliant trade." 10-K: currently exempt for "most products and materials" but "no assurance" exemptions continue. April 2 tariff deadline is within the window.

The Bull Case

2027 Margin Recovery | LR 1.2

CEO: "we see our chocolate business in 2027 increase its margin in a considerable way." CFO: "If cocoa ranges at around 3,000, our goal is to get into 2027 with a much improved situation... 2027 can really be a step change."

Real and significant. But our window closes July 10. Market won't reprice until Q3/Q4 2026 at earliest as FY27 visibility improves. Time-horizon mismatch -- value investors buying for 2027 are the counterparty, and they're probably right on their clock.

Buyback Support | LR 1.1

≈$575M/quarter at FY25 pace. At $58: ≈10M shares/quarter (≈0.8% of float). Provides floor support. Accelerated in Q4 (9M shares). But can't overcome fundamental headwinds relative to QQQ.

Forward Valuation | LR 1.0

yfinance forward P/E shows 17.24x, but this is NTM-blended pulling in FY27 recovery. FY26-only P/E = $58.27 / $3.05 midpoint = 19.1x. The 17.24x is flattering. The 19.1x is what you're actually paying for this year.

NTM consensus ≈$3.38 implies Q1 2027 at ≈$0.94 vs Q1 2026's $0.61 -- a 54% YoY improvement. The street is already pricing the step-change narrative.

Dividend Yield 3.47% | LR 1.0

Attracts income investors. Irrelevant to 15-week QQQ-relative performance.

Market Consensus

What the Market Knows (Everything We Know)

Every piece of the bear case is consensus. The $1B Q1 EBIT hit is in the guidance. The cocoa hedge trap is on the transcript. The NA volume weakness is in the 10-K. There is zero informational edge.

What the Options Market Prices

Implied earnings move (extracted from term structure, Apr 17 pre-earnings vs Jun 18 post-earnings):

Variance(Jun 18, 57td) = (0.327)^2 x 57/252 = 0.02418
Variance(Apr 17, 14td) = (0.286)^2 x 14/252 = 0.00454

Incremental: 0.01964 (43 trading days, 1 is earnings)
Non-event daily var: 0.000325 to 0.000381
42 non-event days: 0.01364 to 0.01600

Earnings-day variance: 0.00364 to 0.00601
Implied move: +/-6.0% to +/-7.7%
Central: +/-6.8% (≈$54.31 to $62.23)

Normal staple earnings move: +/-3-4%. Market is pricing ≈1.7x typical. Elevated but justified by the $1B EBIT hit uncertainty.

Options Positioning (Jun 18, 41K OI -- the liquid chain)

Puts (floor): OI-weighted center at $52.18 (-10.4%). Biggest concentrations: $52 (6,420 OI), $50 (5,729 OI), $55 (4,848 OI). Protection for bad Q1 + 52-week low retest.

Calls (ceiling): OI-weighted center at $63.36 (+8.7%). Biggest concentrations: $65 (7,319 OI), $60 (5,410 OI). Likely covered calls -- holders selling upside against positions, willing to exit at $65.

P/C OI: 1.13 (neutral, slight bearish tilt). IV Rank 116% (above 52-week range). Put skew +31.8% vs ATM (elevated, ≈2x normal staple skew).

The Consensus Narrative

"MDLZ is a 2026 transition year / 2027 recovery story. Q1 will be ugly (known). Hold for yield and the margin step-change when cocoa hedges reset."

Consensus expected path: flat to slightly down through Q1 earnings, stabilizing $55-62, with gradual re-rate starting Q3/Q4 2026 as FY27 visibility improves.

What Is Mispriced

Nothing material in MDLZ stock. The market is roughly correct on fundamentals. The "mispricing" is structural:

1. Index construction inefficiency. QQQ is forced to include MDLZ at 0.40% because it's a top-100 Nasdaq non-financial. The methodology doesn't optimize for factor coherence. We have discretion to remove. The index doesn't.

2. Competitive hedging asymmetry (second-order). MDLZ locked into expensive hedges while competitors can undercut. Requires cross-referencing peers (HSY, NSRGY) -- not widely modeled. Closest thing to a non-consensus signal but weak.

3. Reported vs adjusted headline risk. Q1 reported EPS could be near-zero while adjusted hits $0.61. A 1-3 day overreaction to ugly headlines, not a structural mispricing.

Counterparty Analysis

Who buys MDLZ here: Income/value investors (3.47% yield, ≈16x FY27), index/passive flows, those front-running 2027 chocolate recovery.

Their horizon: 12-24 months. They're willing to eat Q1 ugliness for FY27 step-change.

Our edge (three sources, none informational):

1. Structural. QQQ beta ~ 0.04 factor misfit. Index includes MDLZ mechanically. We have discretion.
2. Temporal. 15-week window aligns with Q1 trough. Value investors pricing 2027 are on a different clock.
3. Factor mismatch. Anti-momentum consumer staple in a growth/tech index. Systematic drag in QQQ-relative terms.

Reflexivity check: Stock price doesn't affect fundamentals. Cocoa costs, consumer demand, and hedging positions don't change because MDLZ trades at $55 or $65. Reality adjudicates regardless of sentiment.

Who's short: 2.8% of float, 3.5 days to cover. Not crowded. Not a battleground.

Insider Activity

• Form 4 (Jan 13): Laura Stein, EVP/General Counsel. 1,716 shares at $55.09 via tax withholding on DSU vesting (code F). Non-signal.
• 13G/A (Mar 27): Vanguard internal realignment. Non-signal.

No open-market buying or selling. Insider signal: neutral.

Key Dates

Expected Contribution

Basket weight: 0.40%
Expected MDLZ underperformance vs QQQ (15 weeks): 5-10%
Filtration alpha contribution: 2-4 bps

This is the smallest remove in the basket. High conviction
(structural, clean), negligible payoff. Correct but barely matters.

The removes that drive the basket: CRWD (1.02%), VRTX (0.92%),
MELI (0.70%), CMCSA (0.65%).

Kill Conditions

1. Cocoa spikes above $5,000 -- competitors also suffer, MDLZ hedge looks prescient
2. Consumer confidence inflection -- NA biscuit volume recovery
3. Tariff policy benefits MDLZ (USMCA protected, competitors hit)
4. Stock drops to $48-50 range -- 2027 recovery starts getting priced in early, downside exhausted

Summary Statistics